participants will be enrolled in this multicenter study. Primary Objective: Determine progression-free survival (PFS) [time frame: start of induction, osimertinib up to 22 months] Secondary Objectives: Determine time to appearance of new metastases [time frame
Search Results
Nan Du, Tian Xie, and Xinsheng Cheng
nomogram model was conducted based on the result of multivariate analyses including age, race, T stage, N stage, distant metastases. AUC was 0.769. Age was divided into 4 groups by using RCS, and the optimal cut-off points for age were 40, 52 and 60 years
be enrolled in this multicenter study. Primary Objective: Determine progression-free survival (PFS) [time frame: start of induction, osimertinib up to 22 months] Secondary Objectives: Determine time to appearance of new metastases [time frame: start
distant metastases compared with other breast cancer types. Effective targeted breast cancer strategies, including endocrine agents and HER2-directed therapies, are not active against these tumors. In the NCCN Guidelines, systemic chemotherapy is often
Gianfranco Puppo, Gian Paolo Mattioli, Sara De Magistris, Erilda Kamberi, Maria Serafini, Giordano Riccioni, Yuri Rosati, and Francesca Marchesani
with advanced NSCLC in a real-life context, the efficacy of the treatment was independent of the age. Factors associated with lower survival were the presence of brain or liver metastases or previous treatment with a tyrosine kinase inhibitor (TKI) drug.
Daniel T Cifarelli and Christopher P Cifarelli
months. Metastases and meningiomas comprised 60% of diagnoses. Median age was 62 years with median household income and residential population of $44,752 USD and 7634 people. The one-way mean and median travel distances were 74.6 and 66.3 miles. The total
R. Michael Tuttle and R. Leboeuf
with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy . J Clin Endocrinol Metab 2006 ; 91 : 2892 – 2899 . 6. Robbins RJ Wan Q Grewal RK . Real-time prognosis for metastatic
Supratentorial PNET AMED-2 Standard risk for recurrence The recommendations “Localized brain tumor (<1.5 cm 2 residual tumor); no spine metastases and negative CSF; no disseminated disease” changed to: ▪ No evidence of metastasis (brain, spine
Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
or accepted therapy. Principles of the Management of Metastatic Disease Approximately 50% to 60% of patients diagnosed with CRC develop colorectal metastases, 4 - 6 and 80% to 90% of these patients have unresectable metastatic liver disease
Jonathan M. Loree and Scott Kopetz
liver metastases RAS status appears high in colorectal cancer, ranging from 90% to 100%; however, discordance of up to 32% has been reported between lung or lymph node metastases and primary tumors. 7 , 8 In the reported case, a partial response was
